Termeer: Wanna buy Genzyme for $82/share?

 

 

 

According to Fierce Biotech this morning, the latest market rumor is that Henri Termeer, CEO of Genzyme, has contacted his counterpart at Takeda to determine their interest in buying Genzyme at $82 per share.  Takeda for its part has expressed a desire to break into the US market in a bigger way.  However, the company has been focused on oncology, CNS diseases and metabolic diseases.  Genzyme's portfolio of orphan drugs for rare diseases may not be of strong interest or the best fit for them.

"Genzyme has been apparently talking to different companies to find better match/price and/or force Sanofi to get serious," Michael Obuchowski, chief investment officer at First Empire Asset Management, writes in a message to Bloomberg.  Genzyme desperately wants to find another bidder to move the price above the $80 per share mark, rather than start with Sanofi's $69/share offer price.

  

 

 

 

 

 

 

Posted by Bruce Lehr November 15th 2010.